New weekly diabetes shot shows promise in large trial

NCT ID NCT06235086

Completed Disease control Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested a new weekly injection called TG103, combined with the common diabetes pill metformin, in 632 adults with type 2 diabetes. The goal was to see if TG103 could lower blood sugar better than an existing weekly shot (dulaglutide) over 28 weeks. Participants received either TG103 or dulaglutide, and researchers tracked changes in blood sugar levels, weight, and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TG103 injection (a weekly shot) compared to dulaglutide (another weekly shot)
What this could lead to: If successful, this could offer a new weekly injection option to help people with type 2 diabetes better control their blood sugar and possibly lose weight.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The drug may not prove superior to existing options, and side effects like gastrointestinal issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Peking University People's Hospital

Beijing, Beijing Municipality, 100032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.